Celestica Inc. (CLS) formed multiple bottom with $9.44 target or 9.00% below today’s $10.37 share price. Celestica Inc. (CLS) has $1.41 billion valuation. The stock decreased 0.96% or $0.1 during the last trading session, reaching $10.37. About 348,681 shares traded. Celestica Inc. (NYSE:CLS) has declined 26.94% since April 21, 2017 and is downtrending. It has underperformed by 38.49% the S&P500.
Medifast Inc (MED) investors sentiment increased to 1.33 in 2017 Q4. It’s up 0.33, from 1 in 2017Q3. The ratio has improved, as 93 active investment managers increased and started new equity positions, while 70 trimmed and sold equity positions in Medifast Inc. The active investment managers in our database now possess: 10.23 million shares, up from 10.20 million shares in 2017Q3. Also, the number of active investment managers holding Medifast Inc in top ten equity positions was flat from 1 to 1 for the same number . Sold All: 14 Reduced: 56 Increased: 57 New Position: 36.
Medifast, Inc., through its subsidiaries, produces, distributes, and sells weight loss, weight management, healthy living products, and other consumable health and diet products. The company has market cap of $1.19 billion. The firm offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, eggs, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home, and Essential 1 brands, as well as Dual Fuel, a sports nutrition pilot program. It has a 43.18 P/E ratio. It also provides meal replacements comprising vitamins and minerals; and hydration products, as well as other nutrients for health purposes.
The stock increased 1.91% or $1.85 during the last trading session, reaching $98.89. About 151,093 shares traded. Medifast, Inc. (MED) has risen 107.05% since April 21, 2017 and is uptrending. It has outperformed by 95.50% the S&P500.
Analysts await Medifast, Inc. (NYSE:MED) to report earnings on May, 3. They expect $0.86 EPS, up 68.63% or $0.35 from last year’s $0.51 per share. MED’s profit will be $10.35 million for 28.75 P/E if the $0.86 EPS becomes a reality. After $0.60 actual EPS reported by Medifast, Inc. for the previous quarter, Wall Street now forecasts 43.33% EPS growth.
Engaged Capital Llc holds 2.4% of its portfolio in Medifast, Inc. for 264,549 shares. U S Global Investors Inc owns 28,500 shares or 0.91% of their US portfolio. Moreover, Eam Investors Llc has 0.66% invested in the company for 72,165 shares. The Massachusetts-based Bogle Investment Management L P De has invested 0.4% in the stock. Ativo Capital Management Llc, a Illinois-based fund reported 19,006 shares.
Since January 1, 0001, it had 0 insider buys, and 3 selling transactions for $4.87 million activity.
Among 12 analysts covering Celestica (NYSE:CLS), 3 have Buy rating, 0 Sell and 9 Hold. Therefore 25% are positive. Celestica has $15.5000 highest and $0.75 lowest target. $12.80’s average target is 23.43% above currents $10.37 stock price. Celestica had 36 analyst reports since October 21, 2015 according to SRatingsIntel. The stock of Celestica Inc. (NYSE:CLS) has “Hold” rating given on Thursday, June 22 by Macquarie Research. RBC Capital Markets maintained it with “Hold” rating and $15.0 target in Wednesday, August 16 report. The rating was maintained by Scotia Capital on Thursday, January 25 with “Hold”. As per Wednesday, January 24, the company rating was maintained by Stifel Nicolaus. RBC Capital Markets downgraded it to “Sector Perform” rating and $0.75 target in Friday, October 30 report. The stock has “Hold” rating by Standpoint Research on Friday, November 18. RBC Capital Markets maintained it with “Sector Perform” rating and $14.0 target in Wednesday, October 21 report. As per Friday, July 22, the company rating was upgraded by Canaccord Genuity. Macquarie Research downgraded the stock to “Neutral” rating in Friday, July 29 report. The stock of Celestica Inc. (NYSE:CLS) has “Hold” rating given on Wednesday, August 16 by Stifel Nicolaus.
Analysts await Celestica Inc. (NYSE:CLS) to report earnings on April, 27 before the open. They expect $0.16 earnings per share, down 33.33% or $0.08 from last year’s $0.24 per share. CLS’s profit will be $21.80M for 16.20 P/E if the $0.16 EPS becomes a reality. After $0.10 actual earnings per share reported by Celestica Inc. for the previous quarter, Wall Street now forecasts 60.00% EPS growth.